Medicine and Dentistry
Abemaciclib
29%
Airflow
58%
Airway Obstruction
29%
Association
19%
Atypical Mycobacterium
52%
Calreticulin
52%
Cancer Treatment
17%
Chemotherapy
29%
Chronic Myelomonocytic Leukemia
29%
Chronic Obstructive Pulmonary Disease
52%
Combination Therapy
20%
COVID-19
29%
Culture
43%
Deterioration
31%
Diagnosis
37%
Epidermal Growth Factor Receptor
19%
Hospital
23%
Immune Checkpoint Inhibitor
41%
Infection
19%
Inpatient
20%
Lung
55%
Lung Aspergillosis
19%
Lung Cancer
46%
Lymphocytic Interstitial Pneumonia
29%
Mycetoma
29%
Non Small Cell Lung Cancer
17%
Observational Study
17%
Paracetamol
17%
Paragonimiasis
29%
Patient
100%
Plasma
58%
Pleurisy
29%
Pollen Allergy
29%
Prevalence
33%
Prognosis
31%
Prospective Cohort Study
29%
Pulmonary Sequestration
29%
Receptor Gene
19%
Retrospective Cohort Study
29%
Specimen
22%
Spirometry
39%
Spontaneous Pneumothorax
29%
Surgery
19%
Tezepelumab
29%
Therapeutic Procedure
54%
Thoracoscopy
34%
Tongue
22%
Tuberculosis
19%
Visceral Pleura
41%
Woman
41%
Pharmacology, Toxicology and Pharmaceutical Science
Abemaciclib
29%
Agranulocytosis
9%
Asthma
29%
Blast Cell Crisis
14%
Calreticulin
23%
Chronic Myelomonocytic Leukemia
29%
Cisplatin
8%
Cohort Study
58%
Coronavirinae
29%
Disease
29%
Epidermal Growth Factor Receptor
19%
Ethinylestradiol Plus Megestrol Acetate
5%
Fibrosis
9%
Fluticasone Furoate Plus Umeclidinium Plus Vilanterol
7%
Goserelin
11%
Heat Shock Protein 70
11%
Hemoptysis
29%
Hemoptysis
29%
Histone H3
5%
Immunogenic Cell Death
9%
Letrozole
11%
Lipocortin 1
11%
Loeffler Pneumonia
29%
Lung Cancer
17%
Lung Disease
8%
Malignant Neoplasm
18%
Mepolizumab
29%
Methylprednisolone
9%
Mycobacterium Avium Complex
29%
Non Small Cell Lung Cancer
18%
Pemetrexed
8%
Platinum
5%
Progression Free Survival
8%
Sleep Disordered Breathing
29%
Sulfasalazine
29%
Tezepelumab
29%
Toxicity
8%
Biochemistry, Genetics and Molecular Biology
Airflow
29%
All Cause Mortality
6%
Annexin A1
16%
Antibody Blood Level
29%
Association
13%
Atypical Mycobacterium
29%
Blood Level
41%
Calreticulin
52%
Cancer Cell
5%
Cell Death
21%
Cohort Study
37%
Disease Classification
11%
Electric Potential
11%
Heat Shock Protein
16%
High-Mobility Group
34%
Histone H3
5%
Kinetics
11%
Mycobacterium Avium Complex
29%
Overall Survival
11%
Progression Free Survival
14%
Prospective Cohort Study
29%
Survival Rate
6%
Time
5%